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Abstract
The development of targeted therapies, which benefit only a subgroup of patients treated for a given type of
cancer, has been extremely attractive to many investigators. Adaptive seamless phase II/III designs in oncology
clinical trials with interim analyses for subpopulation selection could be used if pre-defined biomarker hypothesis
exists. We consider the interim analysis using time-to-event endpoints, e.g., overall survival (OS) and progression-
free survival (PFS), to identify whether the whole population or only the biomarker-positive population should
be continued into the subsequent stage, whereas a final decision is based on OS data. In this paper, we propose
the interim decision-making strategies in adaptive designs with correlated endpoints, considering post-progression
survival (PPS) magnitudes. In our approach, the interim decision is made on the basis of predictive power, by
incorporating information on OS as well as PFS. We consider PFS data only in making interim decision in order
to supplement the immature OS data. Simulation studies assuming a targeted therapy show that our interim
decision procedure performs well in terms of selecting the proper population, especially under a scenario in which
PPS affects the translation of the benefit from PFS to OS.
1 Introduction
The development of targeted therapies, which benefit only a subgroup of patients treated for a given type of cancer,
has been extremely attractive to many investigators, especially in oncology. If a pre-defined biomarker hypothesis
exists, clinical trial designs should be set up considering the heterogeneity of patient subgroups by using the biomarker
at the planning stage [1]. Currently, most trials demonstrate the benefit for a given patient subgroup retrospectively.
For instance, it was shown that progression-free survival (PFS) was significantly improved among patients with
pulmonary adenocarcinoma who tested positive for epidermal growth factor receptor (EGFR) inhibitor and received
gefitinib (hazard ratio [95% CI] for PFS: 0.48 [0.36 to 0.64], P < 0.001) [2]. In contrast, PFS was notably worsened
among patients who lacked an EGFR mutation (hazard ratio [95% CI] for PFS, 2.85 [2.05 to 3.98]; P < 0.001). In
another example, both overall survival (OS) and PFS were significantly improved among patients with advanced
colorectal cancer who received cetuximab, and had the wild-type K-ras gene (hazard ratio [95% CI] for PFS, 0.40
[0.30 to 0.54]; P < 0.001; hazard ratio [95% CI] for OS, 0.55 [0.41 to 0.74]; P < 0.001), whereas no improvement
was seen among patients with mutated K-ras tumors (hazard ratio [95% CI] for PFS, 0.99 [0.73 to 1.35]; P = 0.96;
hazard ratio [95% CI] for OS, 0.98 [0.70 to 1.37]; P = 0.89) [3]. Note that the treatment effects for the subgroup in
these clinical trials were evaluated retrospectively. For these reasons, adaptive designs to select the subpopulation
by using an identified biomarker are needed to develop such a therapy.
Interest in the use of adaptive designs has been increasing among many biostatisticians, including staff members
of the Food and Drug Administration from the CDER Office of Epidemiology and Biostatistics, in the past 10 to
15 years [4]. We describe an adaptive seamless phase II/III design with two stages although adaptive designs, in
general, encompass every phases in clinical trials. The different types of adaptive seamless phase II/III designs are
broadly divided into adaptive treatment selection design and adaptive subpopulation selection design. Moreover,
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they can minimize the period, white space, between the analysis of phase II data and the recruitment of phase III
patients [5]. Recently, many papers on adaptive seamless phase II/III designs have been published [5–19]. There are
two methods to combine the stagewise data: the Fisher’s product combination method by Bauer and Ko¨hne [20] and
the weighted inverse normal combination method [21, 22].
In this paper, we discuss an adaptive design for subpopulation selection using correlated time-to-event endpoints.
This design could be applied to the development of targeted therapies. Brannath et al. [13] presented an adaptive
seamless phase II/III methodology for subpopulation selection by using a single time-to-event endpoint. Following
this, Jenkins et al. [15] proposed the aforementioned methodology by using the correlated time-to-event endpoints:
OS and PFS as a short-term endpoint. Subsequently, Friede et al. [19] demonstrated a more powerful method by
using a conditional error function approach [23]. Under the methodology by Jenkins et al. [15], the interim analysis
involves the use of PFS data from stage 1 patients only, whereas the final analysis is conducted based on OS data
from each stage. We propose interim decision-making strategies in adaptive designs for subpopulation selection. We
extend the previous methodologies [13, 15] in two aspects. First, the interim analysis is conducted by incorporating
information on PFS as well as OS. Second, we consider a scenario in which OS is calculated based on post-progression
survival (PPS), if the progression is observed before death.
The paper is structured as follows. We first introduce the approach for final decision-making in adaptive sub-
population selection design using the combination test method proposed by Jenkins et al. [15] in Section 2. We
then discuss the interim decision-making strategies using correlated time-to-event endpoints in Section 3. Section 4
presents a simulation study. Finally, we conclude the paper in Section 5 with a discussion.
2 Final decision-making using combination test approach
This section reviews the combination test approach for final decision-making in adaptive subpopulation selection
design.
We suppose that the pre-defined biomarker hypothesis exists, and the full population F consists of the pre-defined
biomarker-positive population P and the biomarker-negative population N. In adaptive subpopulation selection
designs, an interim analysis takes place to identify whether F or P benefit based on stage 1 only. Subsequently, the
final analysis would conduct hypotheses testing in both F and P, or only in P.
In the combination test for a single one-sided null hypothesis H
{g}
0
for each population g ∈ {F, P}, a stagewise p-
value p
{g}
k for H
{g}
0
is calculated from OS data only for stage k ∈ {1, 2} patients based on log-rank tests. As Jenkins
et al. [15] have illustrated in the solution for time-to-event endpoints in adaptive seamless design, the additional
follow-up during stage 2 of patients accrued in stage 1 contributes to stage 1 p-values. The intersection hypothesis is
H
{F,P}
0
= ∩g∈{F,P}H
{g}
0
. Closed testing procedures [24] are used to strongly control the familywise error rate. We
shall use Simes’ procedure [25] for H
{F,P}
0
with p
{F,P}
k = min[2 ·min(p
{F}
k , p
{P}
k ),max(p
{F}
k , p
{P}
k )].
We then use a weighted inverse normal combination method with pre-specified weights wk, where 0 ≤ wk ≤ 1 and∑2
k=1 w
2
k = 1. For OS data, we set wk =
√
Dk/
∑
j Dj as the weights with the anticipated numbers of OS events
Dk in order to combine the p-value from each stage k and the null hypothesis for each population is rejected if the
weighted inverse normal combination function
C(p
{g}
1
, p
{g}
2
) = w1Φ
−1(1− p
{g}
1
) + w2Φ
−1(1 − p
{g}
2
) > c (1)
where Φ(·) denotes the cumulative distribution function of the standard normal distribution and c ≈ 1.96 represents
the critical value for a one-sided significance level of 0.025. Note that it is vital to specify the combination function
and the design of stage 1 at the planning stage.
3 Interim decision-making
The purpose of this paper is to extend the recent methodologies [13, 15] for interim decision-making in two aspects.
First, not only PFS data but also OS data are incorporated into the interim analysis in adaptive subpopulation
selection design. PFS is defined as the time from randomization until objective tumor progression or death from
any cause, namely, time-to-progression (TTP) or OS, whichever occurs first [26]. Several authors have discussed the
issues in using PFS [27–30]). Although the most commonly used endpoint required in phase III trials by regulatory
agencies is OS, PFS is frequently used in phase II trials, especially for targeted therapies. OS generally requires
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long follow-up durations after tumor progression. Therefore, a long study duration and a large number of patients is
required, making it expensive to conduct clinical trials to collect OS data. Hence, it would be practical to use PFS
data for interim decision-making only if PFS could be deemed as a short-term intermediate time-to-event endpoint,
because it is more quickly observed than OS. Second, we assume a scenario in which OS is calculated considering
PPS after tumor progression, if progression is observed before death. OS data frequently require long-term follow-up
periods. Therefore, it would also be pragmatic to consider the impact based on PPS data.
3.1 Procedures for interim decision-making
An interim analysis takes place to identify whether the full population F or the pre-defined biomarker-positive
population P benefit based on stage 1 only. In addition, a clinical trial can be discontinued early for futility, when
the success of the trials at the interim analysis is deemed unpromising. This enables sponsors and investigators to
optimize the investment of resources. In contrast, there is no consideration to stop the clinical trial early based on
efficacy. For interim decisions, the sponsor has to be blinded to any results at the interim stage and the Independent
Data Monitoring Committee (IDMC) makes the recommendation based on an interim decision rule [31].
3.2 Correlation model between OS and PFS
Several papers have been published to handle the correlation between time-to-event endpoints [32–36]. To measure
the correlation between two time-to-event variables such as PFS and OS, the correlation coefficient by Spearman [37],
which is nonparametric, is widely used in clinical trial reports (see, e.g., [38, 39]. However, these measurements do
not account for censoring.
One of the statistical models to handle censoring has been proposed by Fleischer et al. [36]. They use exponential
models for each time-to-event endpoint based on the assumption that TTP and OS are completely independent and
that PFS is given by the minimum of TTP and OS. Moreover, we shall consider the time-to-event endpoint D, say
the time to death without tumor progression. Then, OS is calculated as follows:
OS =
{
PFS if PFS 6= TTP
TTP + PPS otherwise
.
Suppose that each time-to-event endpoint v ∈ {TTP,PPS,D} is exponentially distributed with parameter λv where
λv > 0. Then the correlation between OS and PFS is given by
ρ = Corr(OS,PFS) =
λPPS√
λ2
TTP
+ 2λTTPλD + λ2PPS
(2)
Note that ρ = 1.0 if no tumor progression occurs before death; in other words, PFS = OS.
3.3 Interim decision rule using predictive power
In this paper, the decision tool applied at the interim analysis relies on the predictive power approach [11, 40]. The
predictive power indicates how likely the various null hypotheses are to be rejected at the final analysis. For instance,
if the predictive power based on interim results is greater than the threshold for one hypothesis, then the possibility of
rejection is high for the corresponding hypothesis when continuing with the corresponding population. For simplicity,
let us assume non-informative priors for the treatment effect; the predictive power for each population s ∈ {F, P,N}
using the interim e ∈ {OS,PFS} data is given as follows:
PP {s}e = 1−
[
Φ
(
1−Π{s}e
)−1/2(
c ·
√
Π
{s}
e − z
{s}
e
)]
where Π
{s}
e represents the event fraction at the interim analysis and z
{s}
e is the observed test statistic based on the
log-rank test using stage 1 data.
In the context of adaptive subpopulation selection designs, Brannath et al. [13] have demonstrated the decision
rule by using the predictive probability as well as the posterior probability at the interim analysis, whereas Jenkins
et al. [15] have proposed the use of the rule based on the estimated hazard ratios. For the clinical development
of targeted therapies, when we consider a scenario in which the experimental treatment is beneficial for P but is
actually harmful for N, the problem of crossing hazard rates might be observed due to the violation of the proportional
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hazard assumption. Hence, we provide the interim decision rule using predictive power for the sake of simplicity by
modifying the rule demonstrated by Brannath et al. [13] and by considering the use of multiple endpoints at the
interim analysis. Figure 1 illustrates the decision rule at the interim stage.
Let pi
{s}
i denote the threshold of the predictive power for each population s ∈ {F, P,N} in each case i and let
δe denote the relative importance that we assign to the corresponding endpoint e ∈ {OS,PFS}. Because of the
nature that PFS data are more quickly observed than OS data, we should reflect the expected number of events
accrued up to the interim analysis. For adaptive treatment selection design, Di Scala and Glimm [41] combined
the predictive probability using weights similar to δe and have shown the simulation results. However, we evaluate
multiple endpoints separately in considering the inconsistency as well as the correlation between OS and PFS due to
the impact of PPS. A series of simulations are needed to set those thresholds to be used by the IDMC.
4 Simulation study
In this section, we describe a simulation study to show the operating characteristics of adaptive subpopulation
selection designs based on the interim decision-making strategies presented in Section 3. The design assumption and
simulation setting are presented in Section 4.1. Furthermore, each probability at the interim or the final decision is
shown in Section 4.2.
4.1 Design assumption and simulation setting
We shall consider a randomized, parallel group clinical trial with two arms, experimental (E ) and control (C ).
Assume that the median TTP for C is 2 months and the median PPS for C is set to (0.5, 0.5, 0.5) or (0.5, 2.0, 3.0)
months, corresponding to the correlation between OS and PFS ρ = (0.9, 0.7, 0.5). The clinical trial consists of two
stages, namely, a randomized phase II trial and a confirmatory phase III trial.
Assume that the patients classified as being either biomarker-positive or biomarker-negative are included in the
trial in order to consider a targeted therapy. Suppose that the prevalence of P among F is roughly set as γ = 50%.
Let HR
{t}
v denote the hazard ratio for each population t ∈ {P,N} using the interim v ∈ {TTP,PPS,D} data. We
consider several scenarios for the treatment effect:
(Scenario 1): HR
{P}
v = 0.50 and HR
{N}
v = 0.90
(Scenario 2): HR
{P}
v = 0.50 and HR
{N}
v = 1.00
(Scenario 3): HR
{P}
v = 0.50 and HR
{N}
v = 1.11
(Scenario 4): HR
{P}
v = 0.50 and HR
{N}
v = 1.43
where a hazard ratio less than 1 indicates an increased benefit from E. Scenarios 1 to 4 are those in which the
experimental treatment is extremely beneficial for P, i.e., HR
{P}
v = 0.50, and the hazard ratio for P for TTP, PPS,
and D is similar for the sake of simplicity. In scenario 1, E is more beneficial for P than for N. Scenario 2 is the
scenario in which E is beneficial for P but not for N. In scenarios 3 and 4, E is beneficial for P but actually harmful for
N. In calculating the predictive power in Section 3.3, it is required to take into account N as well as F and P in these
scenarios. Furthermore, the hazard ratio for F is considered as HR
{F}
v = exp{γ · logHR
{P}
v + (1− γ) · logHR
{N}
v }.
Note that the scenario 3 above is roughly based on a real trial for patients with advanced colorectal cancer
receiving cetuximab [3]. That result shows that the hazard ratios among patients with the wild-type K-ras gene
are HR
{P}
PFS
= 0.40 and HR
{P}
OS
= 0.55 while the hazard ratios among patients with mutated K-ras tumors are
HR
{N}
PFS
= 0.99 and HR
{N}
OS
= 0.98, respectively.
Moreover, we assume that the final analysis is performed after 300 OS events occur in reference to the example [3].
An interim analysis is conducted after τ =(25%, 33%, 50%) PFS events of pre-planned OS events are observed. Here,
we assume that the overall number of patients is 400.
In terms of interim decision-making, the thresholds that needed to be pre-specified at the planning stage are
roughly set as (pi
{F}
1
, pi
{P}
1
, pi
{N}
1
, pi
{P}
2
) = (10%, 5%, 5%, 20%) with weights of δOS = 1/2 and δPFS = 1, respectively,
because OS is a primary endpoint whereas PFS data are more rapidly observed than OS data.
With respect to data generation within the simulation, each time-to-event endpoint is assumed to arise from the
exponential distribution considering the correlation between OS and PFS as well as the impact of PPS after tumor
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progression using Equation (2) as we demonstrated in Section 3.2. Selected results for the simulation are presented
in Section 4.2. Furthermore, the comparison of approaches that use OS data only or PFS data only at the interim
analysis is also given.
4.2 Simulation results
All subsequently reported results are obtained based on 10,000 simulation replications per scenario.
First, Table 1 provides the probability of rejecting at least one null hypothesis for F or P for HR
{P}
OS
= HR
{P}
PFS
=
HR
{N}
OS
= HR
{N}
PFS
= 1.00, under the assumption that the median PPS for C is set to (0.5, 0.5, 0.5) months. It
demonstrates that the familywise type I error rate is controlled at less than 2.5% across all scenarios. The correlation
of the p-values between F and P and the independence of stagewise p-values across stages are provided to confirm
that the assumption of the Simes’ procedure and the weighted inverse normal combination method are met. The
correlation of p-values between F and P is positive and the independence between stage 1 and stage 2 is also
illustrated under all scenarios.
Second, Tables 2 and 3 show the each probability of selecting each corresponding population at the interim
analysis. The lower probability is better in Table 2, whereas the higher is better in Table 3, because of the simulation
setting in which the targeted therapy is considered. It is expected to see a greater probability of selecting each
population when using OS and PFS, under the assumption that the median PPS for C is set to (0.5, 2.0, 3.0)
months, particularly where the correlation between OS and PFS is not very strong, i.e., ρ = (0.7, 0.5), in scenarios 1
to 3. These indicate that the impact of PPS leads to the misspecification of the population rather than the correlation
between OS and PFS. On the other hand, each probability is similar under the assumption that median PPS for
C is set to (0.5, 0.5, 0.5) months for every scenario. In addition, the probability of discontinuing the trial early for
futility is less than 10% under every scenario in Table 4, and this would be valid in terms of the targeted therapy
setting for simulations, although it depends on the pre-specified thresholds.
Lastly, Tables 5 and 6 show the each probability of rejecting the null hypothesis, i.e., power, for each population at
the final analysis. The weighted inverse normal combination method is used here (see, Equation (1) in Section 2). Note
that the lower power is better because it is beneficial only for P in Table 5. Therefore, incorporation of information
from OS and PFS results in good performance in the same way as described in Tables 2 and 3. Furthermore, each
overall power gets lower when the timing of the interim analysis τ is earlier, because of the immature OS and PFS
data. However, an interim decision conducted after the observation of PFS events constituting 50% of the pre-
planned OS events would be unrealistic, due to the adaptive seamless phase II/III clinical trial design considered.
More patients may be needed in order to construct the adaptive seamless phase II/III design.
5 Discussion
The aim of this paper was to propose the interim decision-making strategies in adaptive designs for subpopulation
selection. Interim decision-making strategies using OS as well as PFS perform well in terms of selecting the most
appropriate population, especially under a scenario in which PPS affects the translation of the benefit from PFS to
OS, although there are concerns about bias with respect to operational facets.
This paper has been limited to a situation in which the source of the pre-defined subgroup regarded as biomarker-
positive for efficacy is known. Moreover, a restriction in our simulation results is that sample size calculation is not
considered for the sake of simplicity. In practice, this is determined based on the expected treatment effect for both F
and P. However, a large number of patients would be required when the experimental treatment benefits P but has
a negative effect on N, especially in scenario 4 of Section 4.1. This is a realistic scenario referring to an actual trial
for gefitinib [2]. Alternative clinical trial designs that enroll only P, i.e., enrichment designs [1], could be considered,
particularly in scenarios in which the prevalence of P is small. Meanwhile, note that the aforementioned approach
meets the regulatory requirement in that it provides the efficacy results for N.
In oncology, whether PFS instead of OS as a primary endpoint is acceptable for a given treatment evaluation for
marketing approval will depend on the disease setting. Nevertheless, we consider PFS data only in making interim
decision to supplement the immature OS data. Furthermore, we also consider PPS lengths in using the correlation
between OS and PFS. Consequently, the probability of selecting the proper population at the interim analysis is
improved under the circumstance in which a relatively long PPS is expected. However, as Zhang et al. [42] have
mentioned, the OS benefit given the PFS benefit also depends largely on the crossover rate, because treatment
crossover from the control to experimental groups frequently occurs right after tumor progression in real trials.
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Regarding the correlation of multiple time-to-event endpoints, it would be worthwhile to consider the impact of
crossover rates in addition to the magnitude of PPS.
Regarding multiplicity issues, we use the Simes’ procedure to control the familywise type I error rate. As presented
in Section 4.2, however, these results are conservative because of the asymptotic bivariate normal distribution and
positive correlation. As Friede et al. [19] have proposed, the method based on the conditional error function approach
would be more powerful.
As shown in Section 3.3, we assume non-informative priors at the time of interim decision-making for simplicity
in this paper. A possible future investigation is to consider how external information or any other knowledge prior to
the phase II trial might be incorporated into the use of informative priors and setting the thresholds for the predictive
power in the interim decision.
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Table 1: The familyeise type I error rate, the correlation of the p-values between F and P, and the independence
of stagewise p-values across stages under the assumption that the median PPS for C is set to (0.5, 0.5, 0.5) months
based on 10,000 simulation replications per scenario.
τ ρ Correlation between Familywise
p
{F}
1
and p
{F}
2
p
{P}
1
and p
{P}
2
p
{F,P}
1
and p
{F,P}
2
p
{F}
1
and p
{P}
1
p
{F}
2
and p
{P}
2
typeI error rate
25% 0.90 -0.0001 0.0079 0.0039 0.6261 0.3351 0.0159
0.70 0.0004 0.0034 0.0051 0.6330 0.3240 0.0142
0.50 0.0069 0.0038 0.0072 0.6277 0.3325 0.0155
33% 0.90 0.0157 0.0003 0.0016 0.6207 0.4220 0.0125
0.70 0.0169 0.0041 0.0088 0.6128 0.4121 0.0124
0.50 0.0088 -0.0043 -0.0009 0.6095 0.4180 0.0134
50% 0.90 0.0094 0.0162 0.0111 0.6303 0.6269 0.0179
0.70 0.0022 -0.0002 -0.0002 0.6355 0.6278 0.0154
0.50 0.0069 -0.0013 -0.0020 0.6213 0.6295 0.0189
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Table 2: Probabilities of selecting each population at the interim analysis using the corresponding data under the
assumption that the median PPS for C is set to (0.5, 0.5, 0.5) months based on 10,000 simulation replications per
scenario.
τ HR
{N}
v ρ Probabilities of selecting F using Probabilities of selecting P using
PFS only OS only OS and PFS PFS only OS only OS and PFS
25% 0.90 0.90 0.7718 0.7838 0.7463 0.2120 0.2032 0.2360
0.70 0.7703 0.7606 0.7407 0.2127 0.2159 0.2386
0.50 0.7687 0.7609 0.7523 0.2140 0.2168 0.2275
1.00 0.90 0.6611 0.6658 0.6246 0.3182 0.3166 0.3524
0.70 0.6597 0.6614 0.6258 0.3197 0.3091 0.3487
0.50 0.6596 0.6559 0.6436 0.3182 0.3166 0.3317
1.11 0.90 0.5379 0.5348 0.4919 0.4371 0.4441 0.4800
0.70 0.5321 0.5462 0.4985 0.4405 0.4194 0.4688
0.50 0.5334 0.5405 0.5169 0.4395 0.4277 0.4537
1.43 0.90 0.2338 0.2076 0.1900 0.7302 0.7613 0.7702
0.70 0.2355 0.2585 0.2096 0.7282 0.6935 0.7474
0.50 0.2390 0.2576 0.2224 0.7238 0.6989 0.7372
33% 0.90 0.90 0.7172 0.7375 0.6879 0.2704 0.2526 0.2973
0.70 0.7188 0.7095 0.6853 0.2678 0.2714 0.2977
0.50 0.7185 0.7138 0.7038 0.2687 0.2686 0.2819
1.00 0.90 0.5777 0.5795 0.5394 0.4048 0.4068 0.4407
0.70 0.5884 0.5827 0.5498 0.3950 0.3933 0.4294
0.50 0.5829 0.5842 0.5639 0.4008 0.3933 0.4179
1.11 0.90 0.4269 0.4101 0.3764 0.5508 0.5733 0.5986
0.70 0.4285 0.4402 0.3931 0.5505 0.5302 0.5803
0.50 0.4325 0.4373 0.4132 0.5470 0.5344 0.5640
1.43 0.90 0.1274 0.1049 0.0959 0.8420 0.8686 0.8699
0.70 0.1300 0.1496 0.1103 0.8388 0.8074 0.8521
0.50 0.1291 0.1483 0.1183 0.8412 0.8150 0.8489
50% 0.90 0.90 0.5978 0.6179 0.5545 0.3915 0.3757 0.4337
0.70 0.5953 0.5846 0.5479 0.3936 0.3958 0.4358
0.50 0.5923 0.5871 0.5660 0.3955 0.3964 0.4197
1.00 0.90 0.4067 0.4104 0.3595 0.5795 0.5804 0.6251
0.70 0.4110 0.4115 0.3643 0.5744 0.5639 0.6158
0.50 0.4139 0.4125 0.3867 0.5701 0.5655 0.5956
1.11 0.90 0.2408 0.2293 0.1973 0.7428 0.7587 0.7838
0.70 0.2439 0.2518 0.2087 0.7375 0.7171 0.7669
0.50 0.2435 0.2509 0.2242 0.7367 0.7226 0.7539
1.43 0.90 0.0310 0.0204 0.0183 0.9496 0.9626 0.9587
0.70 0.0295 0.0388 0.0227 0.9469 0.9218 0.9469
0.50 0.0298 0.0391 0.0258 0.9454 0.9274 0.9474
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Table 3: Probabilities of selecting each population at the interim analysis using the corresponding data under the
assumption that the median PPS for C is set to (0.5, 2.0, 3.0) months based on 10,000 simulation replications per
scenario.
τ HR
{N}
v ρ Probabilities of selecting F using Probabilities of selecting P using
PFS only OS only OS and PFS PFS only OS only OS and PFS
25% 0.90 0.90 0.7718 0.7838 0.7463 0.2120 0.2032 0.2360
0.70 0.7794 0.7970 0.7213 0.2043 0.1953 0.2589
0.50 0.7790 0.7635 0.6950 0.2059 0.2089 0.2766
1.00 0.90 0.6611 0.6658 0.6246 0.3182 0.3166 0.3524
0.70 0.6684 0.6673 0.5830 0.3117 0.3208 0.3923
0.50 0.6710 0.6642 0.5689 0.3094 0.3009 0.3943
1.11 0.90 0.5379 0.5348 0.4919 0.4371 0.4441 0.4800
0.70 0.5461 0.5140 0.4373 0.4293 0.4706 0.5323
0.50 0.5397 0.5394 0.4225 0.4362 0.4179 0.5327
1.43 0.90 0.2338 0.2076 0.1900 0.7302 0.7613 0.7702
0.70 0.2343 0.1648 0.1256 0.7315 0.8091 0.8319
0.50 0.2294 0.2390 0.1371 0.7363 0.6983 0.8020
33% 0.90 0.90 0.7172 0.7375 0.6879 0.2704 0.2526 0.2973
0.70 0.7251 0.7392 0.6563 0.2602 0.2520 0.3248
0.50 0.7214 0.7022 0.6220 0.2648 0.2674 0.3470
1.00 0.90 0.5777 0.5795 0.5394 0.4048 0.4068 0.4407
0.70 0.5811 0.5774 0.4848 0.3997 0.4096 0.4899
0.50 0.5750 0.5701 0.4603 0.4066 0.3923 0.5007
1.11 0.90 0.4269 0.4101 0.3764 0.5508 0.5733 0.5986
0.70 0.4317 0.3935 0.3169 0.5447 0.5895 0.6529
0.50 0.4201 0.4267 0.3013 0.5566 0.5298 0.6508
1.43 0.90 0.1274 0.1049 0.0959 0.8420 0.8686 0.8699
0.70 0.1231 0.0811 0.0541 0.8429 0.8919 0.9029
0.50 0.1241 0.1295 0.0605 0.8446 0.8021 0.8792
50% 0.90 0.90 0.5978 0.6179 0.5545 0.3915 0.3757 0.4337
0.70 0.6014 0.6380 0.5186 0.3893 0.3577 0.4687
0.50 0.5985 0.5873 0.4722 0.3927 0.3885 0.5040
1.00 0.90 0.4067 0.4104 0.3595 0.5795 0.5804 0.6251
0.70 0.4135 0.4137 0.3086 0.5743 0.5784 0.6745
0.50 0.4122 0.4149 0.2872 0.5757 0.5515 0.6833
1.11 0.90 0.2408 0.2293 0.1973 0.7428 0.7587 0.7838
0.70 0.2411 0.2159 0.1441 0.7427 0.7745 0.8346
0.50 0.2425 0.2475 0.1394 0.7428 0.7112 0.8237
1.43 0.90 0.0310 0.0204 0.0183 0.9496 0.9626 0.9587
0.70 0.0339 0.0147 0.0076 0.9458 0.9719 0.9680
0.50 0.0345 0.0324 0.0102 0.9463 0.9121 0.9440
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Table 4: Probabilities of discontinuing the trial early for futility at the interim analysis using the corresponding data
based on 10,000 simulation replications per scenario.
τ HR
{N}
v ρ Probabilities of discontinuing the trial early for futility under the assumption that
median PPS for C = (0.5, 0.5, 0.5) months median PPS for C = (0.5, 2.0, 3.0) months
PFS only OS only OS and PFS PFS only OS only OS and PFS
25% 0.90 0.90 0.0162 0.0130 0.0177 0.0162 0.0130 0.0177
0.70 0.0170 0.0235 0.0207 0.0163 0.0077 0.0198
0.50 0.0173 0.0223 0.0202 0.0151 0.0276 0.0284
1.00 0.90 0.0207 0.0176 0.0230 0.0207 0.0176 0.0230
0.70 0.0206 0.0295 0.0255 0.0199 0.0119 0.0247
0.50 0.0222 0.0275 0.0247 0.0196 0.0349 0.0368
1.11 0.90 0.0250 0.0211 0.0281 0.0250 0.0211 0.0281
0.70 0.0274 0.0344 0.0327 0.0246 0.0154 0.0304
0.50 0.0271 0.0318 0.0294 0.0241 0.0427 0.0448
1.43 0.90 0.0360 0.0311 0.0398 0.0360 0.0311 0.0398
0.70 0.0363 0.0480 0.0430 0.0342 0.0261 0.0425
0.50 0.0372 0.0435 0.0404 0.0343 0.0627 0.0609
33% 0.90 0.90 0.0124 0.0099 0.0148 0.0124 0.0099 0.0148
0.70 0.0134 0.0191 0.0170 0.0147 0.0088 0.0189
0.50 0.0128 0.0176 0.0143 0.0138 0.0304 0.0310
1.00 0.90 0.0175 0.0137 0.0199 0.0175 0.0137 0.0199
0.70 0.0166 0.0240 0.0208 0.0192 0.0130 0.0253
0.50 0.0163 0.0225 0.0182 0.0184 0.0376 0.0390
1.11 0.90 0.0223 0.0166 0.0250 0.0223 0.0166 0.0250
0.70 0.0210 0.0296 0.0266 0.0236 0.0170 0.0302
0.50 0.0205 0.0283 0.0228 0.0233 0.0435 0.0479
1.43 0.90 0.0306 0.0265 0.0342 0.0306 0.0265 0.0342
0.70 0.0312 0.0430 0.0376 0.0340 0.0270 0.0430
0.50 0.0297 0.0367 0.0328 0.0313 0.0684 0.0603
50% 0.90 0.90 0.0107 0.0064 0.0118 0.0107 0.0064 0.0118
0.70 0.0111 0.0196 0.0163 0.0093 0.0043 0.0127
0.50 0.0122 0.0165 0.0143 0.0088 0.0242 0.0238
1.00 0.90 0.0138 0.0092 0.0154 0.0138 0.0092 0.0154
0.70 0.0146 0.0246 0.0199 0.0122 0.0079 0.0169
0.50 0.0160 0.0220 0.0177 0.0121 0.0336 0.0295
1.11 0.90 0.0164 0.0120 0.0189 0.0164 0.0120 0.0189
0.70 0.0186 0.0311 0.0244 0.0162 0.0096 0.0213
0.50 0.0198 0.0265 0.0219 0.0147 0.0413 0.0369
1.43 0.90 0.0194 0.0170 0.0230 0.0194 0.0170 0.0230
0.70 0.0236 0.0394 0.0304 0.0203 0.0134 0.0244
0.50 0.0248 0.0335 0.0268 0.0192 0.0555 0.0458
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Table 5: Probabilities of rejecting the null hypothesis for each population at the final analysis using the corresponding
data under the assumption that the median PPS for C is set to (0.5, 0.5, 0.5) months based on 10,000 simulation
replications per scenario.
τ HR
{N}
v ρ Probabilities of rejecting H
{F}
0
using Probabilities of rejecting H
{P}
0
using
PFS only OS only OS and PFS PFS only OS only OS and PFS
25% 0.90 0.90 0.5136 0.5224 0.5020 0.1799 0.1728 0.2006
0.70 0.3989 0.4012 0.3893 0.1491 0.1532 0.1679
0.50 0.4027 0.4037 0.3985 0.1547 0.1569 0.1651
1.00 0.90 0.2348 0.2399 0.2283 0.2687 0.2658 0.2962
0.70 0.1863 0.1921 0.1822 0.2230 0.2170 0.2426
0.50 0.1923 0.1951 0.1897 0.2289 0.2284 0.2399
1.11 0.90 0.0649 0.0657 0.0620 0.3615 0.3685 0.3979
0.70 0.0620 0.0675 0.0614 0.3072 0.2936 0.3278
0.50 0.0619 0.0651 0.0616 0.3127 0.3034 0.3236
1.43 0.90 0.0003 0.0002 0.0002 0.5952 0.6203 0.6299
0.70 0.0009 0.0010 0.0009 0.4942 0.4719 0.5090
0.50 0.0014 0.0015 0.0014 0.4954 0.4809 0.5060
33% 0.90 0.90 0.5969 0.6154 0.5797 0.2530 0.2373 0.2785
0.70 0.4982 0.5029 0.4829 0.2266 0.2312 0.2530
0.50 0.5037 0.5073 0.4974 0.2299 0.2294 0.2406
1.00 0.90 0.3443 0.3514 0.3309 0.3770 0.3789 0.4104
0.70 0.2836 0.2902 0.2745 0.3302 0.3311 0.3591
0.50 0.2927 0.2989 0.2879 0.3373 0.3323 0.3512
1.11 0.90 0.1374 0.1387 0.1297 0.5107 0.5318 0.5563
0.70 0.1190 0.1273 0.1144 0.4585 0.4421 0.4852
0.50 0.1229 0.1282 0.1197 0.4585 0.4489 0.4735
1.43 0.90 0.0018 0.0016 0.0018 0.7738 0.7987 0.8006
0.70 0.0042 0.0049 0.0041 0.6868 0.6655 0.7004
0.50 0.0044 0.0044 0.0043 0.6974 0.6774 0.7046
50% 0.90 0.90 0.5875 0.6085 0.5467 0.3896 0.3738 0.4316
0.70 0.5564 0.5545 0.5192 0.3800 0.3838 0.4213
0.50 0.5602 0.5590 0.5378 0.3831 0.3841 0.4069
1.00 0.90 0.3864 0.3925 0.3453 0.5765 0.5770 0.6215
0.70 0.3625 0.3710 0.3281 0.5528 0.5449 0.5935
0.50 0.3715 0.3761 0.3509 0.5504 0.5478 0.5750
1.11 0.90 0.2121 0.2083 0.1785 0.7377 0.7539 0.7789
0.70 0.1920 0.2088 0.1714 0.7077 0.6917 0.7380
0.50 0.2003 0.2103 0.1882 0.7100 0.6989 0.7274
1.43 0.90 0.0171 0.0122 0.0117 0.9410 0.9554 0.9512
0.70 0.0147 0.0226 0.0124 0.9028 0.8847 0.9053
0.50 0.0153 0.0230 0.0144 0.9079 0.8948 0.9108
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Table 6: Probabilities of rejecting the null hypothesis for each population at the final analysis using the corresponding
data under the assumption that the median PPS for C is set to (0.5, 2.0, 3.0) months based on 10,000 simulation
replications per scenario.
τ HR
{N}
v ρ Probabilities of rejecting H
{F}
0
using Probabilities of rejecting H
{P}
0
using
PFS only OS only OS and PFS PFS only OS only OS and PFS
25% 0.90 0.90 0.5136 0.5224 0.5020 0.1799 0.1728 0.2006
0.70 0.6583 0.6779 0.6162 0.1976 0.1890 0.2505
0.50 0.5825 0.5865 0.5330 0.1908 0.1925 0.2555
1.00 0.90 0.2348 0.2399 0.2283 0.2687 0.2658 0.2962
0.70 0.3258 0.3333 0.2969 0.3007 0.3093 0.3792
0.50 0.2691 0.2836 0.2432 0.2842 0.2765 0.3629
1.11 0.90 0.0649 0.0657 0.0620 0.3615 0.3685 0.3979
0.70 0.0797 0.0809 0.0716 0.4126 0.4529 0.5124
0.50 0.0682 0.0752 0.0609 0.3967 0.3800 0.4864
1.43 0.90 0.0003 0.0002 0.0002 0.5952 0.6203 0.6299
0.70 0.0001 0.0001 0.0001 0.6965 0.7677 0.7923
0.50 0.0002 0.0003 0.0002 0.6591 0.6280 0.7216
33% 0.90 0.90 0.5969 0.6154 0.5797 0.2530 0.2373 0.2785
0.70 0.6862 0.7038 0.6261 0.2591 0.2509 0.3234
0.50 0.6369 0.6309 0.5595 0.2604 0.2635 0.3420
1.00 0.90 0.3443 0.3514 0.3309 0.3770 0.3789 0.4104
0.70 0.4356 0.4409 0.3798 0.3977 0.4077 0.4876
0.50 0.3715 0.3883 0.3176 0.3991 0.3861 0.4924
1.11 0.90 0.1374 0.1387 0.1297 0.5107 0.5318 0.5563
0.70 0.1684 0.1646 0.1397 0.5414 0.5861 0.6491
0.50 0.1323 0.1505 0.1110 0.5450 0.5212 0.6392
1.43 0.90 0.0018 0.0016 0.0018 0.7738 0.7987 0.8006
0.70 0.0006 0.0011 0.0006 0.8362 0.8851 0.8962
0.50 0.0008 0.0018 0.0008 0.8208 0.7814 0.8560
50% 0.90 0.90 0.5875 0.6085 0.5467 0.3896 0.3738 0.4316
0.70 0.5999 0.6368 0.5177 0.3892 0.3575 0.4686
0.50 0.5930 0.5835 0.4690 0.3922 0.3881 0.5035
1.00 0.90 0.3864 0.3925 0.3453 0.5765 0.5770 0.6215
0.70 0.4097 0.4113 0.3075 0.5741 0.5781 0.6743
0.50 0.3966 0.4038 0.2799 0.5745 0.5510 0.6824
1.11 0.90 0.2121 0.2083 0.1785 0.7377 0.7539 0.7789
0.70 0.2278 0.2088 0.1390 0.7426 0.7744 0.8345
0.50 0.2117 0.2279 0.1290 0.7414 0.7104 0.8225
1.43 0.90 0.0171 0.0122 0.0117 0.9410 0.9554 0.9512
0.70 0.0152 0.0084 0.0043 0.9456 0.9717 0.9678
0.50 0.0122 0.0152 0.0054 0.9446 0.9110 0.9425
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Figure 1: Interim decision rule
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